Last updated: April 25, 2026
Which suppliers control naltexone manufacturing in the US market?
Naltrexone is a long-established opioid antagonist with multiple marketed strengths (oral and injectable) and a mature generic supply chain. In the absence of a single, universally binding “supplier list” for all forms (oral tablets vs extended-release injectable), market coverage depends on the specific product (brand or generic), strength, dosage form, and whether the drug is sourced from finished-dose manufacturers or API/DP subcontractors.
Actionable supplier map by product type (US):
Oral naltrexone tablets (generic and brand)
Common US market supply is split across:
- Finished-dose generic manufacturers supplying labeled tablets directly to distribution channels.
- Contract manufacturers producing tablets for multiple labelers.
- API suppliers providing naltrexone active pharmaceutical ingredient to tablet formers.
Extended-release naltrexone injection
Supply is concentrated in companies that can run long-acting injectable platforms with:
- Specialized sterile manufacturing
- Controlled formulation and filling
- Long batch-release lead times tied to suspension chemistry and device/process requirements
Who supplies naltrexone API versus finished dosage forms?
The naltrexone supply chain typically separates into two layers:
API suppliers
API manufacturers provide naltrexone bulk drug substance to finished-dose producers via:
- DMF-backed submissions
- NDA/ANDA chemistry references
- Commercial API supply agreements
Finished-dose suppliers (tablet makers, sterile injectables)
Finished-dose manufacturers source API and run:
- Formulation + blending
- Tableting, coating, packaging (oral)
- Sterile manufacturing, filling, lyophilization/suspension process control (injectables)
What do patent-prosecution and formulation realities imply about supplier qualification?
For a business investing in or sourcing naltrexone, qualification requirements differ by dosage form:
- Oral tablets: bioequivalence-sensitive formulation and robust GMP tablet process control
- Extended-release injection: sterile injectable GMP and a validated controlled-release manufacturing process
What suppliers should buyers screen when sourcing naltrexone?
Screening should focus on capability, regulatory standing, and commercial reliability:
Regulatory and quality
- US FDA inspection outcomes for oral solid dose and sterile injectable lines
- DMF holders (API) and ANDA/labeler record (finished dose)
- Compliance history in the relevant dosage form facility
Commercial capability
- Batch size capacity for tablet or long-acting injectable volumes
- Lead time for API-to-finished conversion
- Supply continuity (historical shortages and backorders at the labeler level)
How to translate “supplier” into procurement-ready categories
For procurement, treat “supplier” as one of three vendor types rather than a single list:
| Supplier category |
What they provide |
What buyers validate |
| API supplier |
Naltrexone bulk substance |
DMF status, test methods, CoA release specs |
| Formulation/DP manufacturer |
Tablets (oral) or long-acting injection drug product |
Site GMP record, batch release cadence, stability program |
| Finished-dose labeler |
Branded or generic packaged drug |
Market availability, distribution terms, labeler QA release |
Key takeaways
- Naltrexone supply is dosage-form specific: oral tablet supply chains differ from extended-release injectable platforms.
- Treat “supplier” as API vs finished-dose vs labeler. Mixing these categories creates procurement risk.
- Qualification should be anchored on FDA inspection readiness, DMF/ANDA linkage, and site-level ability for the specific dosage form.
FAQs
1) Are naltrexone tablet suppliers the same as extended-release injection suppliers?
No. Extended-release injectable supply requires sterile long-acting manufacturing capability that typically sits in different, more specialized facilities.
2) How do buyers confirm whether a vendor supplies API or finished dosage?
Confirm whether the vendor holds an API DMF (API supplier) or operates as a contract manufacturer/labeler with ANDA/NDA product responsibility (finished dose).
3) What is the fastest way to reduce supplier qualification risk for oral naltrexone?
Source from finished-dose suppliers with established ANDA/labeler records for the specific strength and packaging format, and tie API qualification to the finished-dose DMF/quality system linkage.
4) What drives pricing differences among naltrexone suppliers?
Dosage form manufacturing complexity, sterile and controlled-release process capability (for injection), facility utilization, and batch release lead times.
5) Which supplier category matters most for launch or scale-up?
For manufacturing control and predictability, the API-to-drug-product interface matters most: buyers should manage both API reliability and finished-dose batch-release capacity.
References
[1] U.S. Food and Drug Administration (FDA). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
[2] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] FDA. Drug Master Files (DMF) and related guidance for holders and users. https://www.fda.gov/drugs/drug-master-files-dmf
[4] FDA. Current Good Manufacturing Practice (cGMP) regulations for drugs. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-cgmp-regulations-drugs
